3
Participants
Start Date
April 19, 2020
Primary Completion Date
January 6, 2021
Study Completion Date
January 6, 2021
MT-3921 Low dose
MT-3921 Low dose, intravenous, single dosing
Thomas Jefferson University, Philadelphia
VA Commonwealth Univ. School of Medicine, Richmond
Vidant Medical Center, Greenville
Carolinas Healthcare System / Atrium Health, Charlotte
University of Mississippi Medical Center, Jackson
The Ohio State University Wexner Medical Center, Columbus
University of Michigan, Ann Arbor
Medical College of Wisconsin, Milwaukee
Northwestern University / Shirley Ryan Ability LAB (SRALAB), Chicago
Carle Foundation Hospital, Urbana
Washington University School of Medicine, St Louis
University of New Mexico Hospital, Albuquerque
UC Davis Medical Center, Sacramento
Lead Sponsor
Mitsubishi Tanabe Pharma America Inc.
INDUSTRY